It’s a remarkable honeymoon GSK and Samsung Biologics are enjoying. Already linked by one major deal, the companies have furthered their relationship with a larger contract.
In this one, U.K. drugmaker GSK will pay (PDF) Korean contract manufacturer Samsung Biologics $296 million in a deal that runs through 2030.
A regulatory filing that revealed the contract did not specify which medicines Samsung will produce. It did show that the contract figure adds up to nearly 27% of Samsung’s sales revenue in 2021.
The deal comes as Samsung is opening what it has dubbed its “Super Plant”—the fourth manufacturing facility at the company’s sprawling complex in Incheon, South Korea. Samsung spent $2 billion to build the Super Plant. In all, the company’s plans call for six factories to be constructed at the site as Samsung is making an ambitious push to become a major player in the CDMO arena.
In May of 2020, GSK and Samsung hooked up on a $231 million, eight-year deal to produce biologic products including lupus drug Benlysta.
That deal came on the heels of Samsung pairing with Vir Biotechnology on a $362 million contract to produce antibodies. That agreement also involved GSK as the company partnered with Vir in a COVID-19 antibody program.
By Kevin Dunleavy
The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.
Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.